MP14-19 LYMPH NODE METASTASES IN GLEASON ≤ 6 PROSTATE CANCER: DATA FROM A GERMAN MULTICENTER DATABASE

Daniel Schindele, Martin Schostak(Aturo), Simon Blaschke, Stefan Hinz(Charité - Universitätsmedizin Berlin), Annette Reinicke, Margit Zacharias(Auguste-Viktoria-Klinik), Robert Kössler(Evangelisches Krankenhaus Königin Elisabeth Herzberge), D. Baumunk(Klinikum Magdeburg), Jan Fichtner(Klinik Niederrhein), Tom Fischer(Klinikum im Friedrichshain), Ulrich Witzsch, Kurt Miller(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Alexander Winter(Klinikum Oldenburg), Sebastian Schäfers(Klinikum Kassel)
The Journal of Urology
March 31, 2015
10.1016/j.juro.2015.02.881
Cited by 0

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218